神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NBIX 神经分泌生物科学

休市中 11-22 16:00:00 EST

125.65

+0.65

+0.52%

盘后125.65

+0.000.00%

19:27 EST

最高127.00	最低124.38	成交量120.68万
今开125.18	昨收125.00	日振幅2.10%
总市值127.22亿	流通市值125.76亿	总股本1.01亿
成交额1.52亿	换手率1.21%	流通股本1.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NBIX","market":"US","secType":"STK","nameCN":"神经分泌生物科学","latestPrice":125.65,"timestamp":1732309200000,"preClose":125,"halted":0,"volume":1206787,"hourTrading":{"tag":"盘后","latestPrice":125.65,"preClose":125.65,"latestTime":"19:27 EST","volume":26033,"amount":3271237.55,"timestamp":1732321676001},"delay":0,"floatShares":100085446,"shares":101246911,"eps":3.727899,"marketStatus":"休市中","marketStatusCode":7,"change":0.65,"latestTime":"11-22 16:00:00 EST","open":125.18,"high":127,"low":124.38,"amount":151609990.34357,"amplitude":0.02096,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.727899,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732525200000},"adr":0,"listingDate":832824000000,"adjPreClose":125,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":126.58,"preClose":125,"latestTime":"08:55 EST","volume":37,"amount":4675.27005,"timestamp":1732283736904},"postHourTrading":{"tag":"盘后","latestPrice":125.65,"preClose":125.65,"latestTime":"19:27 EST","volume":26033,"amount":3271237.55,"timestamp":1732321676001},"volumeRatio":1.0005581543029303,"impliedVol":0.3098,"impliedVolPercentile":0.2619},"requestUrl":"/m/hq/s/NBIX","defaultTab":"news","newsList":[{"id":"2480360155","title":"神经分泌生物科学2024财年第三财季实现净利润1.30亿美元，同比增加56.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480360155","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480360155?lang=zh_cn&edition=full","pubTime":"2024-11-04 00:00","pubTimestamp":1730649642,"startTime":"0","endTime":"0","summary":"11月4日，神经分泌生物科学公布财报，公告显示公司2024财年第三财季净利润为1.30亿美元，同比增加56.44%；其中营业收入为6.22亿美元，同比增加24.65%，每股基本收益为1.28美元。从资产负债表来看，神经分泌生物科学总负债8.16亿美元，其中短期债务34.80百万美元，资产负债比为4.34，流动比率为4.37。机构评级：截至2024年11月4日，当前有24家机构对神经分泌生物科学目标价做出预测，其中目标均价为163.62美元，其中最低目标价为121.00美元，最高目标价为192.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104000110a211d2cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104000110a211d2cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX"],"gpt_icon":0},{"id":"1122819822","title":"异动解读 | 神经分泌生物科学股价大涨近11% 财报利好因素或是推手","url":"https://stock-news.laohu8.com/highlight/detail?id=1122819822","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122819822?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:35","pubTimestamp":1730295329,"startTime":"0","endTime":"0","summary":"神经分泌生物科学(NBIX)今日盘中股价大涨10.99%,报收于91.24美元。市场对该公司最新一季度财报的反应或是导致股价大涨的主要推手。\n\n财报显示,公司第三季度营收同比增长24.7%至6.221亿美元,超过了华尔街分析师的平均预期6.0063亿美元。然而,公司调整后每股收益1.24美元却低于分析师预期的1.51美元。\n\n尽管业绩数据喜忧参半,但分析师对该公司的长期前景持乐观态度。目前,华尔街对公司的平均评级为\"买入\",预期12个月目标股价为168美元。公司在生物技术和医药领域的未来增长潜力,或是导致股价今日大涨的主要因素之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NBIX"],"gpt_icon":0},{"id":"2479783703","title":"神经分泌生物科学盘中异动 大幅上涨10.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479783703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479783703?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:31","pubTimestamp":1730295108,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日21时31分，神经分泌生物科学股票出现波动，股价急速拉升10.79%。截至发稿，该股报128.73美元/股，成交量9.185万股，换手率0.09%，振幅4.55%。神经分泌生物科学股票所在的制药行业中，整体跌幅为5.36%。其相关个股中，神经分泌生物科学、Flora Growth Corp.、Mira Pharmaceuticals, Inc.涨幅较大，Shuttle Pharmaceuticals Holdings, Inc.、Flora Growth Corp.、Sunshine Biopharma Inc.较为活跃，换手率分别为15.93%、14.50%、1.39%，振幅较大的相关个股有Flora Growth Corp.、Intra-Cellular Therapies Inc.、神经分泌生物科学，振幅分别为4.66%、4.63%、4.55%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103021314895bd8df5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103021314895bd8df5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LU2065169927.USD","LU2065170008.USD","LU2065171311.SGD","LU0109394709.USD","NBIX","LU0320765992.SGD","BK4139","LU2324357040.USD","LU0823416689.USD","LU2065171402.SGD"],"gpt_icon":0},{"id":"2479000832","title":"Neurocrine Biosciences Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2479000832","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479000832?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:20","pubTimestamp":1730294443,"startTime":"0","endTime":"0","summary":"   * Neurocrine Biosciences Inc   公布的截至9月30日的季度调整后每股收益为1.24美元，高于去年同期的每股收益82美分。华尔街预期为每股收益 1.26 美元至 2.12 美元。* Neurocrine Biosciences 公司公布的本季度每股收益为 1.24 美元。* 公司报告的季度净收入为 1.298 亿美元。* Neurocrine Biosciences Inc的股价本季度上涨了0.8%，今年迄今为止下跌了11.8%。华尔街对 Neurocrine Biosciences Inc 的 12 个月目标价中位数为 168.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neurocrine Biosciences Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","BK4139","LU2065171402.SGD","LU0889565916.HKD","NBIX","LU0823416689.USD","LU0320765992.SGD","LU2065169927.USD","LU2324357040.USD","LU2065170008.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2478248843","title":"Neurocrine Biosciences Inc   预计每股收益1.51美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2478248843","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478248843?lang=zh_cn&edition=full","pubTime":"2024-10-28 21:00","pubTimestamp":1730120445,"startTime":"0","endTime":"0","summary":"   * Neurocrine Biosciences Inc    将于10月30日公布截至2024年9月30日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，24位分析师的平均预期显示，这家总部位于加利福尼亚州圣地亚哥的公司的营收将从去年同期的4.988亿美元增至6.00628亿美元，增幅为20.4%。* LSEG 分析师对 Neurocrine Biosciences Inc 的平均预期为每股收益 1.51 美元。* 华尔街对 Neurocrine Biosciences Inc 的 12 个月目标价中位数为 168.00 美元，高于其最后收盘价 116.08 美元。10月28日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neurocrine Biosciences Inc   预计每股收益1.51美元 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"gpt_icon":0},{"id":"2475986782","title":"美国研究综述-Autozone, State Street, UnitedHealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2475986782","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475986782?lang=zh_cn&edition=full","pubTime":"2024-10-16 14:42","pubTimestamp":1729060967,"startTime":"0","endTime":"0","summary":"要闻             * Autozone Inc   ：Roth MKM恢复买入评级，目标价3634美元。* 高盛   ：巴克莱将目标价从565美元上调至588美元             * ServiceNow Inc   ：杰富瑞将目标价从900美元上调至1100美元             * State Street Corp   ：巴克莱将目标价从 103 美元上调至 108 美元             * UnitedHealth   ：Leerink Partners将目标价从620美元下调至600美元 以下是路透周三报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU0345769631.USD","LU0731783048.USD","BK4592","LU1323610961.USD","LU0868494617.USD","LU2456880835.USD","IE0004445239.USD","PNC","SAGE","TSCO","IE00BFXG1179.USD","LU0965508806.USD","IE00B1XK9C88.USD","UNH","LU0943347566.SGD","LU0081259029.USD","BK4177","IE0034235188.USD","LU1894683348.USD","LU1934455863.HKD","LU0114720955.EUR","LU0130518102.USD","IE0004091025.USD","IBKR","IE00BZ9MQY76.HKD","JNJ","NBIX","SCHW","LU0306806265.USD","LU0345770993.USD","LU1894683264.USD","PEN","SVCO","COTY","ORLY","AAP","AZO","LU1506573853.SGD","LU1066051225.USD","OMC","EXEL","LU0162691827.USD","STT","NOW","LU0345769128.USD","KDP","IE00B2B36J28.USD","LU0306807586.USD"],"gpt_icon":1},{"id":"2470703554","title":"更新版 3-更正-百时美施贵宝公司新型精神分裂症药物获美国 FDA 批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2470703554","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470703554?lang=zh_cn&edition=full","pubTime":"2024-09-27 07:04","pubTimestamp":1727391881,"startTime":"0","endTime":"0","summary":"更新版 3-更正-百时美施贵宝公司新型精神分裂症药物获美国 FDA 批准周五盘前股价上涨 6新型精神分裂症治疗药物获得 FDA 批准布里斯托尔公司将药物定价为每月 1,850 美元更新 9 月 26 日的报道，在第 2 段和第 3 段增加了有关其他抗精神病药物的细节，在第 4 段增加了有关股票的细节Bhanvi Satija/Michael Erman. FDA 批准该药的依据是两项研究的数据，在这两项研究中，服用该药的患者症状明显减轻。精神分裂症会导致持续的妄想和幻觉，严重影响患者对现实的感知。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240926:nL4S3L823P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211328371.USD","LU0882574055.USD","BK4581","LU1585245621.USD","IE0002141913.USD","LU1023059063.AUD","BK4559","LU1571399168.USD","LU1989771016.USD","LU2242652126.USD","LU0320765992.SGD","BK4007","LU1074936037.SGD","ABBV","LU1093756168.USD","LU1061106388.HKD","LU0795875169.SGD","LU1057294990.SGD","LU0943347566.SGD","LU0310800379.SGD","IE00BJJMRZ35.SGD","LU0061475181.USD","LU1261432733.SGD","LU0256863811.USD","LU0321505868.SGD","BMY","LU0114720955.EUR","LU1244550221.USD","LU0203347892.USD","LU1003077747.HKD","LU1093756325.SGD","LU1670710588.SGD","LU0122379950.USD","LU0211327993.USD","LU0225771236.USD","LU0985481810.HKD","LU0128525929.USD","BK4532","BK4566","LU0868494617.USD","NBIX","LU0237698245.USD","IE0004445239.USD","IE00BJT1NW94.SGD","VNDA","LU0708994859.HKD","BK4139","LU0553294199.USD","LU0310799852.SGD","LU0225284248.USD"],"gpt_icon":0},{"id":"2467778520","title":"BUZZ--美国股票走势-Atea Pharmaceuticals、Adobe、Similarweb","url":"https://stock-news.laohu8.com/highlight/detail?id=2467778520","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467778520?lang=zh_cn&edition=full","pubTime":"2024-09-13 21:21","pubTimestamp":1726233701,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      9月13日 - 华尔街周五有望小幅高开，因为投资者重新评估了美联储下周加大降息力度的可能性，而波音公司则在该公司工厂工人罢工后下跌。美东时间9:08，道指电子盘  上涨0.23%，报41,239点。标普500指数小型股  上涨0.22%，报收于5,614.5点；纳斯达克100指数小型股  下跌0.01%，报收于19,445.75点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","HK0000320223.HKD","LU0516422952.EUR","LU0070302665.USD","PK","WYNN","NBIX","RH","LU0370786039.SGD","IE00B0JY6N72.USD","LU0965508806.USD","LU0140636845.USD","ADBE","LU0157215616.USD","LU0307460666.USD","LU0516423091.SGD","HAL","IE0004445239.USD","LU0300736492.USD","LU0588546209.SGD","GEHC","LU0650527681.SGD","LU0861579265.USD","UPWK","NUE","SMWB","NEM","LU0823416689.USD","IE00B3M56506.USD","NFE","LU0170899867.USD","LU0175139822.USD","HST","DRH","HK0000320264.USD","IE00B19Z3B42.SGD","LU1023059493.AUD","AVIR","L","LU0496367417.USD","LU2326559502.SGD","APLE","LU0472753341.HKD","LU0124676726.USD","STLD","RLJ","CAL"],"gpt_icon":1},{"id":"2467729717","title":"BUZZ--美国股票走势-波音公司、金矿公司、甲骨文公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2467729717","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467729717?lang=zh_cn&edition=full","pubTime":"2024-09-13 20:01","pubTimestamp":1726228892,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      9月13日 - 美国股指期货周五小幅走高，原因是投资者重新评估了美联储下周大幅降息的可能性，而波音公司股价则在该公司工厂工人罢工后下跌。美东时间7:45，道指电子盘  上涨0.15%，报41,209点。标普500指数  上涨0.18%，报5612.25点；纳斯达克100指数  上涨0.03%，报19452.75点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","BA","STLD","ORCL","CAL","LU2498475776.HKD","LU0417517546.SGD","LU1934455194.USD","LU0157215616.USD","LU0965509101.SGD","LU2065171402.SGD","LU0496367417.USD","LU1366333091.USD","RLJ","LU2065171311.SGD","BK4218","HAL","LU0965509010.AUD","BK4588","LU0300736492.USD","LU0124676726.USD","BK4139","LU0175139822.USD","LU0256863811.USD","LU0330918003.SGD","LU0889565833.HKD","LU0075056555.USD","LU0055631609.USD","IE00BBT3K403.USD","LU0689626769.HKD","LU0965508806.USD","LU0823416689.USD","LU0070302665.USD","NEM","LU1934455277.USD","LU0861579265.USD","IE00BMPRXN33.USD","LU0368265764.SGD","LU2065170008.USD","NUE","IE00B19Z4B17.USD","LU0323591593.USD","BK4585","LU2065169927.USD","NBIX","LU1223082519.USD","GEHC","BK4097","IE00BLSP4239.USD","LU2462611646.USD"],"gpt_icon":1},{"id":"2467573480","title":"更新版 1-试验失败，Neurocrine 停止开发精神分裂症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2467573480","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467573480?lang=zh_cn&edition=full","pubTime":"2024-09-13 05:04","pubTimestamp":1726175065,"startTime":"0","endTime":"0","summary":"     路透9月12日 - Neurocrine Biosciences   周四表示，由于在一项中期试验中没有达到主要目标，该公司将停止开发旨在改善精神分裂症患者认知功能的实验性药物。Neurocrine公司表示，它将把资源集中用于其他精神分裂症和抑郁症候选药物的后期开发。该公司股价在延时交易中下跌了 2.5%。上个月，该公司表示，其另一种精神分裂症药物NBI-1117568在一项中期试验中有助于减轻症状的严重程度，但人们担心这种益处能否在更大规模的试验中得到复制 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU2065169927.USD","LU0823416689.USD","LU2065171402.SGD","LU2065171311.SGD","LU0109394709.USD","BK4139","LU2065170008.USD","LU0889565916.HKD","LU0320765992.SGD","NBIX"],"gpt_icon":0},{"id":"2467273105","title":"BUZZ-停止开发精神分裂症药物，Neurocrine Biosciences业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2467273105","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467273105?lang=zh_cn&edition=full","pubTime":"2024-09-13 05:01","pubTimestamp":1726174908,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    9月12日 - ** 制药商Neurocrine Biosciences  盘后交易股价上涨1.1%，报120美元** 该公司将停止 (link) 试验药物的开发，该药物在中期试验测试中未达到主要目标。** 该药物名为luvadaxistat，正在作为一种潜在的治疗手段进行测试，以改善精神分裂症患者的认知功能。** NBIX 表示将集中资源进行其他精神分裂症和抑郁症候选药物的后期开发** 截至上次收盘，该公司股价累计下跌 7.8","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0823416689.USD","BK4139","LU2065171402.SGD","LU2324357040.USD","LU0889565916.HKD","LU2065169927.USD","LU0109394709.USD","LU2065171311.SGD","NBIX","LU2065170008.USD"],"gpt_icon":0},{"id":"2467360227","title":"Neurocrine公司的实验性药物未能达到精神分裂症试验的主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2467360227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467360227?lang=zh_cn&edition=full","pubTime":"2024-09-13 04:28","pubTimestamp":1726172904,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透9月12日 - Neurocrine Biosciences公司  称，在一项旨在改善精神分裂症患者认知功能的中期试验中，其实验性药物没有达到主要目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU0889565916.HKD","LU2065171311.SGD","LU0109394709.USD","LU2065169927.USD","LU0320765992.SGD","LU0823416689.USD","LU2065171402.SGD","NBIX","BK4139","LU2324357040.USD"],"gpt_icon":0},{"id":"1116161171","title":"期权女巫 | 投资者可出售这5只股票的看涨期权来获得收入，交易思路如下","url":"https://stock-news.laohu8.com/highlight/detail?id=1116161171","media":"期权女巫","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116161171?lang=zh_cn&edition=full","pubTime":"2024-09-03 15:05","pubTimestamp":1725347111,"startTime":"0","endTime":"0","summary":"看涨期权是一种衍生品合约，赋予持有者以预设的行权价购买股票的权利。美国银行称，为了降低购买该看涨期权的成本，投资者还可以通过卖出到期日较晚的另一个期权来“roll out”其备兑看涨期权头寸，或者通过卖出到期日相同但行权价更高的看涨期权来“roll up”头寸。","market":"us","thumbnail":"https://community-static.tradeup.com/news/3bec209c5f9de0832f596e425ec010c9","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/3bec209c5f9de0832f596e425ec010c9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"期权女巫 | 投资者可出售这5只股票的看涨期权来获得收入，交易思路如下","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX","DKS","CAR","ALB","FSLR"],"gpt_icon":1},{"id":"2463140672","title":"美国研究综述-Neurocrine Biosciences、Centerspace、Veeva Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=2463140672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463140672?lang=zh_cn&edition=full","pubTime":"2024-08-29 15:13","pubTimestamp":1724915615,"startTime":"0","endTime":"0","summary":"    路透8月29日 - 华尔街证券分析师周四修改了对几家美国上市公司的评级和目标价，其中包括 Neurocrine Biosciences、Centerspace 和 Veeva Systems。要点              * Neurocrine Biosciences Inc   ：Piper Sandler将其评级从中性上调至增持             * Centerspace   ：Raymond James将目标价从75美元上调至82美元             * Veeva Systems Inc   ：杰富瑞将目标价从225美元上调至240美元 以下是路透周四报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COO","CSR","LU2286300806.USD","MODG","LU0082616367.USD","FSUN","OKTA","IE00BZ1G4Q59.USD","PSTG","NTNX","LU1267930227.SGD","PDCO","GILD","LU1585245621.USD","BK4578","IE00B894F039.SGD","LU0251142724.SGD","TWFG","KSS","LU1852331112.SGD","NTAP","CRWD","VEEV","BNZI","WISA","ZG","SJM","EVS.SI","FIVE","TTC","GWRE","LU2236285917.USD","PVH","NBIX","BK4579","HAIN","ESS","LU2468319806.SGD","CPB","LU0792757196.USD","BBWI","BK4198","DCI","WOLF","FL"],"gpt_icon":1},{"id":"2463930644","title":"BUZZ--美国股票走势-伯克希尔-哈撒韦公司、超级微型计算机、精灵美人","url":"https://stock-news.laohu8.com/highlight/detail?id=2463930644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463930644?lang=zh_cn&edition=full","pubTime":"2024-08-29 00:06","pubTimestamp":1724861180,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      8月28日 - 周三，在人工智能领军企业Nvidia发布财报之前，纳斯达克指数领跌美国股指，市场关注芯片公司和其他科技相关股票引领的近期牛市涨势能否持续。美东时间11:32，道琼斯工业平均指数  下跌0.22%，报41161.48点。标普500指数  下跌0.66%，报5588.66点；纳斯达克综合指数  下跌1.37%，报17511.225点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STWD","WMB","TRU","AVAV","AVB",".IXIC","ANF","MRO",".SPX","NEM","KSS","COP","CLF","SJM","BBWI","CTRA","TQQQ","UDR","SMCI","BXP","HEI","PDCO","CDE","MNQmain","PSQ","NBIX","ELF","EQR","SMTC","CHWY","BRK.B","TOL",".DJI","EQT","BKR","EFX","DVN","CVX","BUZZ","AMBA","BRK.A","PVH","NQmain","DXD","MRVI","ESS"],"gpt_icon":1},{"id":"2462684584","title":"BUZZ-Neurocrine 因投资者质疑精神分裂症药物的试验数据而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2462684584","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462684584?lang=zh_cn&edition=full","pubTime":"2024-08-28 21:12","pubTimestamp":1724850776,"startTime":"0","endTime":"0","summary":"    8月28日 - ** 制药商Neurocrine Biosciences  股价盘前下跌15.5%至128.9美元** 该公司称，在一项中期试验中，其20毫克最低剂量的精神分裂症药物NBI-1117568与安慰剂相比，在用于衡量症状严重程度的量表中， ，减少了7.5个点。** 几位分析师还将试验结果与百时美施贵宝公司的  精神分裂症药物KarXT进行了比较。** 结果低于KarXT之前降低的11.6个百分点\"--BMO资本市场部** 截至上次收盘，NBIX股价年累计上涨15.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU0109394709.USD","LU2065171311.SGD","LU0868494617.USD","LU0306807586.USD","LU2133065610.SGD","LU0823416689.USD","LU1718418525.SGD","LU2125154778.USD","BUZZ","LU0321505439.SGD","LU1093756325.SGD","LU0321505868.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4534","LU0456855351.SGD","LU1670710661.SGD","LU1430594728.SGD","NBIX","LU0237698245.USD","LU1032466523.USD","LU1585245621.USD","BK4585","LU2324357040.USD","LU0061475181.USD","BMY","LU1670711123.USD","LU2065171402.SGD","BK4532","LU0320765992.SGD","BK4588","LU0889565916.HKD","BK4007","LU1571399168.USD","LU1670711040.USD","LU2065169927.USD","LU0882574055.USD","LU2242646821.SGD","IE00BSNM7G36.USD","LU1670710588.SGD","LU0225771236.USD","LU1989771016.USD","BK4139","LU0306806265.USD","LU2065170008.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4581","LU1261432733.SGD"],"gpt_icon":1},{"id":"2462402453","title":"Neurocrine公司的精神分裂症药物在中期研究中达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2462402453","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462402453?lang=zh_cn&edition=full","pubTime":"2024-08-28 19:05","pubTimestamp":1724843159,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透8月28日 -    Neurocrine Biosciences   周三称，其治疗成人精神分裂症的实验性药物在一项中期研究中达到了主要目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU0823416689.USD","LU0320765992.SGD","LU2065169927.USD","LU2065171311.SGD","NBIX","LU0109394709.USD","LU2065171402.SGD","BK4139","LU0889565916.HKD","LU2324357040.USD"],"gpt_icon":0},{"id":"2458154745","title":"神经分泌生物科学2024财年第二财季实现净利润65.00百万美元，同比减少31.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458154745","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458154745?lang=zh_cn&edition=full","pubTime":"2024-08-10 00:16","pubTimestamp":1723220217,"startTime":"0","endTime":"0","summary":"8月10日，神经分泌生物科学公布财报，公告显示公司2024财年第二财季净利润为65.00百万美元，同比减少31.94%；其中营业收入为5.90亿美元，同比增加30.24%，每股基本收益为0.64美元。从资产负债表来看，神经分泌生物科学总负债7.96亿美元，其中短期债务35.40百万美元，资产负债比为4.16，流动比率为4.19。机构评级：截至2024年8月10日，当前有24家机构对神经分泌生物科学目标价做出预测，其中目标均价为171.67美元，其中最低目标价为131.00美元，最高目标价为219.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240810001702958c4a27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240810001702958c4a27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX"],"gpt_icon":0},{"id":"2456231070","title":"奥本海默：维持Neurocrine Biosciences(NBIX.US)评级，由优于大市调整至优于大市评级, 目标价由216.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456231070","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456231070?lang=zh_cn&edition=full","pubTime":"2024-08-03 23:52","pubTimestamp":1722700351,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","LU0109394709.USD","LU2065169927.USD","NBIX","LU2065171402.SGD","LU0889565916.HKD","LU2065171311.SGD","LU2065170008.USD","LU0320765992.SGD","LU2324357040.USD","LU0823416689.USD"],"gpt_icon":0},{"id":"1197596591","title":"异动解读 | 神经分泌生物科学公司业绩超预期 股价大涨10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197596591","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197596591?lang=zh_cn&edition=full","pubTime":"2024-08-01 21:38","pubTimestamp":1722519505,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司今日盘中大涨10.57%,报收于150美元左右,引发市场广泛关注。公司此前公布的第二季度业绩显示,总销售额达5.902亿美元,其中神经系统药物Ingrezza的净销售额高达5.838亿美元,均超过了分析师的预期。公司同时上调了Ingrezza全年销售预期,从之前的21亿-22亿美元上调至22.5亿-23亿美元。分析人士表示,作为公司主打产品,Ingrezza未来的销售表现将是决定公司股价走势的关键因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurocrine.com","stockEarnings":[{"period":"1week","weight":0.0699},{"period":"1month","weight":0.0918},{"period":"3month","weight":-0.1777},{"period":"6month","weight":-0.0986},{"period":"1year","weight":0.1322},{"period":"ytd","weight":-0.0464}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neurocrine Biosciences, Inc.于1992年1月在加利福尼亚州注册成立，并于1996年5月在特拉华州重新注册成立。该公司是一家专注于神经科学的生物制药公司，目的很简单：为有巨大需求的人减轻痛苦，但选择很少。三十年来，该公司运用对神经科学以及大脑和身体系统之间相互联系的独特见解，推进用于治疗未得到充分解决的神经、神经内分泌和神经精神疾病的药物，他们将继续不懈地追求药物，以减轻令人衰弱的疾病和紊乱的负担。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.066296},{"month":2,"riseRate":0.321429,"avgChangeRate":-0.00768},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.006842},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.012064},{"month":5,"riseRate":0.571429,"avgChangeRate":0.045557},{"month":6,"riseRate":0.517241,"avgChangeRate":0.019417},{"month":7,"riseRate":0.482759,"avgChangeRate":-0.002747},{"month":8,"riseRate":0.517241,"avgChangeRate":0.020511},{"month":9,"riseRate":0.551724,"avgChangeRate":0.027852},{"month":10,"riseRate":0.551724,"avgChangeRate":0.030047},{"month":11,"riseRate":0.586207,"avgChangeRate":0.038394},{"month":12,"riseRate":0.642857,"avgChangeRate":0.042544}],"exchange":"NASDAQ","name":"神经分泌生物科学","nameEN":"Neurocrine Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神经分泌生物科学,NBIX,神经分泌生物科学股票,神经分泌生物科学股票老虎,神经分泌生物科学股票老虎国际,神经分泌生物科学行情,神经分泌生物科学股票行情,神经分泌生物科学股价,神经分泌生物科学股市,神经分泌生物科学股票价格,神经分泌生物科学股票交易,神经分泌生物科学股票购买,神经分泌生物科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}